Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01945762
Previous Study | Return to List | Next Study

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer (Caprelsa104)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01945762
Recruitment Status : Completed
First Posted : September 19, 2013
Last Update Posted : October 19, 2020
Sponsor:
Collaborator:
Worldwide Clinical Trials
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:
This is a European multinational, multicenter, non-interventional (observational) and prospective study. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative and RET positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic MTC.

Condition or disease Intervention/treatment
Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer (MTC) Drug: Vandetanib 300 mg

Detailed Description:

This is a multinational, multicenter, non-interventional (observational) and prospective study. European countries where vandetanib is on the market will participate in the study.

This study is being conducted to fulfil the specific obligation post-authorisation measure for the conditional marketing authorisation. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative and RET positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic MTC. The clinical benefit of vandetanib (CAPRELSA™) 300 mg has previously been established in a clinical trial (Study 58) on the basis of a clinically and statistically significant advantage in progression free survival (PFS) which was supported by a high response rate and substantial duration of response.

Layout table for study information
Study Type : Observational
Actual Enrollment : 31 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer
Actual Study Start Date : February 17, 2014
Actual Primary Completion Date : June 18, 2020
Actual Study Completion Date : June 18, 2020


Group/Cohort Intervention/treatment
1. patient cohorts (40 patients/cohort)
RET positive patient cohorts
Drug: Vandetanib 300 mg
Vandetanib commercial tablets
Other Name: ZD6474, CAPRELSA

2. patient cohorts (40 patients/cohort)
RET negative patient cohorts
Drug: Vandetanib 300 mg
Vandetanib commercial tablets
Other Name: ZD6474, CAPRELSA




Primary Outcome Measures :
  1. Assessment of Objective Response Rate [ Time Frame: From enrollment until study completion, assessed up to 38 months ]
    Assessment of Objective Response Rate [using Response Evaluation Criteria In Solid Tumours (RECIST) 1.1]

  2. Assessment of Disease control rate [ Time Frame: From enrollment until study completion, assessed up to 38 months ]
    Assessment of Disease control rate [using Response Evaluation Criteria In Solid Tumours (RECIST) 1.1]

  3. Assessment of Duration of Response [ Time Frame: From enrollment until study completion, assessed up to 38 months ]
    Assessment of Duration of Response (using RECIST 1.1)

  4. Assessment of Progression Free Survival [ Time Frame: From enrollment until study completion, assessed up to 38 months ]
    Assessment of Progression Free Survival (using RECIST 1.1)

  5. Evaluation of Safety by assessment of QTc prolongations [ Time Frame: From enrollment until study completion, assessed up to 38 months ]
    Assessment of QTc prolongations

  6. Evaluation of Safety by assessment of Adverse Events [ Time Frame: From enrollment until study completion, assessed up to 38 months ]
    Assessment of Adverse Events

  7. Evaluation of Safety by assessment of vital signs [ Time Frame: From enrollment until study completion, assessed up to 38 months ]
    Assessment of Vital signs

  8. Evaluation of Safety by assessment of laboratory data [ Time Frame: From enrollment until study completion, assessed up to 38 months ]
    Assessment of Laboratory data


Secondary Outcome Measures :
  1. Patient Characteristics [ Time Frame: From enrollment until study completion, assessed up to 38 months ]
    Patient demographics and medical history / Disease characteristics / Death / Treatment information



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer (MTC)
Criteria

Inclusion Criteria:

1. Signed informed consent 2. Male or female aged 18 years or above 3. Histological diagnosis of MTC 4. Patients with symptomatic and aggressive sporadic MTC, who have unresectable, locally advanced/metastatic disease. (The factors considered by the investigator to determine a patient's disease to be symptomatic and aggressive will be recorded in the CRF). 5. Measurable disease:

  • assessment confirmed within the 12 weeks previous to start of treatment, and
  • defined according to RECIST 1.1: at least one lesion, not irradiated, that can be accurately measured as ≥10 mm in the longest diameter (except lymph nodes which must have short axis ≥15 mm) with CT or MRI and which is suitable for accurate repeated measurements. Measurable lesions with calcifications should not be assessed as target lesions unless no other measurable lesion is available. 6. Known definite RET mutation status (definition according to section 3.2). The status should be:
  • for patients prescribed with vandetanib: positive or negative
  • for patients not prescribed with vandetanib: negative RET mutation status must be determined from a tumour sample obtained within 18 months prior to enrollment. It is strongly recommended that a tissue sample obtained within 6 months prior to enrolment is used. 7. For patients newly prescribed vandetanib 300 mg, the prescription should be issued according to marketing authorisation and following the vandetanib Summary of Product Characteristics (SmPC) (Appendix B). The starting dose could be reduced to 200 mg in patients with moderate renal impairment

    • Exclusion criteria

      1. Current or planned inclusion/participation in a clinical trial
      2. Patients already receiving vandetanib or who have received vandetanib for their MTC before the study first visit
      3. Contraindications according to the vandetanib SmPC (not applicable for patients who do not receive vandetanib): (a) Patients with a QT interval corrected for heart rate (QTc) interval over 480 msec: (i) Congenital long QT syndrome (ii) Concomitant use of vandetanib with the following medicinal products known to also prolong the QT interval and / or induce Torsades de pointes: Arsenic, cisapride, erythromycin intravenous (IV), toremifene, mizolastine, moxifloxacin, Class I A and III antiarrhythmics (b) Currently pregnant or breast feeding (c) Hypersensitivity to the active substance or to any of the excipients (d) Severe renal impairment: creatinine clearance < 30 ml/minute calculated by Cockcroft-Gault formula. (See Appendix D). (e) Serum bilirubin greater than 1.5 x the upper limit of reference range (ULRR) (f) Potassium, magnesium or calcium outside the normal laboratory range

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01945762


Locations
Layout table for location information
Belgium
investigational Site Belgium
Belgium, Belgium
France
investigational Site France
France, France
Germany
investigational Site Germany
Germany, Germany
Italy
investigational Site Italy
Italy, Italy
Luxembourg
investigational Site Luxembourg
Luxembourg, Luxembourg
Netherlands
investigational Site Netherlands
Netherlands, Netherlands
Spain
investigational Site Spain
Spain, Spain
United Kingdom
investigational Site United Kingdom
United Kingdom, United Kingdom
Sponsors and Collaborators
Genzyme, a Sanofi Company
Worldwide Clinical Trials
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier: NCT01945762    
Other Study ID Numbers: D4200C00104
OBS14778 ( Other Identifier: Sanofi )
First Posted: September 19, 2013    Key Record Dates
Last Update Posted: October 19, 2020
Last Verified: October 2020
Keywords provided by Sanofi ( Genzyme, a Sanofi Company ):
RET Mutation
DIagnostics
Medullary Thyroid Cancer
MTC
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Carcinoma, Neuroendocrine
Thyroid Diseases
Aggression
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Behavioral Symptoms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue